It is becoming increasingly difficult to separate the interests of the deep state from those of Big Pharma.
“The FDA has asked a federal judge to make the public wait until the year 2076 to disclose all of the data and information it relied upon to license Pfizer’s COVID-19 vaccine,” according to a report by Aaron Siri at Injecting Freedom.
FDA Wants Until 2076 To Fully Release Pfizer Vaccine Data: Lawsuit https://t.co/KLuo3tOtmp
— Jack Posobiec ?? (@JackPosobiec) November 18, 2021
According to a lawsuit filed by Siri’s firm on behalf of non-profit Public Health and Medical Professionals for Transparency, the Food and Drug Administration “has proposed to produce 500 pages” of the relevant documentation “per month which, based on its calculated number of pages, would mean it would complete its production in nearly 55 years – the year 2076.”
Siri says that while “it took the FDA precisely 108 days from when Pfizer started producing the records for licensure to when the FDA licensed the Pfizer vaccine,” the FDA “now asks for over 20,000 days to make these documents available to the public.”
The suit points out that “the acute need for transparency regarding this product is heightened by the fact that the secretary of Health and Human Services, the FDA’s parent department, has granted Pfizer complete immunity from financial liability for any injury caused by its product.”
The FDA’s intransigence comes as the United States government has signed on to “pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment,” according to the New York Post, a treatment for which the drug company has recently sought an emergency use authorization from the FDA.
Today, I’m announcing we have purchased 10 million treatment courses of Pfizer’s antiviral COVID-19 pill. Vaccination is still our most important tool – but this new pill may dramatically reduce hospitalizations and deaths and help accelerate our path out of this pandemic.
— President Biden (@POTUS) November 18, 2021
While Pfizer has recently allowed “generics makers to manufacture its COVID-19 oral antiviral treatment,” according to MarketWatch, CEO Albert Bourla told Barron’s that the company had no plan to do the same with its vaccine:
“It’s a very different story,” Bourla said. “This is a small molecule. A small molecule, there are many qualified generic manufacturers that can make it.
The vaccine is the highest, most challenging technology to manufacture in the world right now; making lipid nanoparticles and storing them in minus seventy degrees. I don’t think in three years someone would be able to make it.”
